1. Home
  2. DCBO vs ABUS Comparison

DCBO vs ABUS Comparison

Compare DCBO & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DCBO
  • ABUS
  • Stock Information
  • Founded
  • DCBO 2016
  • ABUS 2005
  • Country
  • DCBO Canada
  • ABUS United States
  • Employees
  • DCBO N/A
  • ABUS N/A
  • Industry
  • DCBO
  • ABUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • DCBO
  • ABUS Health Care
  • Exchange
  • DCBO Nasdaq
  • ABUS Nasdaq
  • Market Cap
  • DCBO 783.3M
  • ABUS 711.2M
  • IPO Year
  • DCBO 2020
  • ABUS N/A
  • Fundamental
  • Price
  • DCBO $26.75
  • ABUS $4.49
  • Analyst Decision
  • DCBO Strong Buy
  • ABUS Strong Buy
  • Analyst Count
  • DCBO 6
  • ABUS 2
  • Target Price
  • DCBO $41.33
  • ABUS $5.00
  • AVG Volume (30 Days)
  • DCBO 55.9K
  • ABUS 961.2K
  • Earning Date
  • DCBO 11-07-2025
  • ABUS 11-05-2025
  • Dividend Yield
  • DCBO N/A
  • ABUS N/A
  • EPS Growth
  • DCBO 33.51
  • ABUS N/A
  • EPS
  • DCBO 0.69
  • ABUS N/A
  • Revenue
  • DCBO $230,502,000.00
  • ABUS $15,416,000.00
  • Revenue This Year
  • DCBO $13.02
  • ABUS $138.02
  • Revenue Next Year
  • DCBO $8.37
  • ABUS N/A
  • P/E Ratio
  • DCBO $35.21
  • ABUS N/A
  • Revenue Growth
  • DCBO 15.11
  • ABUS 53.23
  • 52 Week Low
  • DCBO $25.50
  • ABUS $2.71
  • 52 Week High
  • DCBO $53.86
  • ABUS $5.10
  • Technical
  • Relative Strength Index (RSI)
  • DCBO 39.45
  • ABUS 56.52
  • Support Level
  • DCBO $25.69
  • ABUS $4.10
  • Resistance Level
  • DCBO $27.23
  • ABUS $4.65
  • Average True Range (ATR)
  • DCBO 0.60
  • ABUS 0.21
  • MACD
  • DCBO -0.02
  • ABUS -0.01
  • Stochastic Oscillator
  • DCBO 45.40
  • ABUS 68.76

About DCBO Docebo Inc.

Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: